Ranitidin_Dyna
Category
Ranitidin_Dyna Brand names, Ranitidin_Dyna Analogs
Ranitidin_Dyna Brand Names Mixture
Tritec (ranitidine bismuth citrate salt)
Ranitidin_Dyna Chemical_Formula
C13H22N4O3S
Ranitidin_Dyna RX_link
http://www.rxlist.com/cgi/generic2/ranitbc.htm
Ranitidin_Dyna fda sheet
Ranitidin_Dyna msds (material safety sheet)
Ranitidin_Dyna Synthesis Reference
B. J. Price et al., U.S. Pat. 4,128,658 (1978)
Ranitidin_Dyna Molecular Weight
314.405 g/mol
Ranitidin_Dyna Melting Point
69-70 oC
Ranitidin_Dyna H2O Solubility
24.7 mg/mL
Ranitidin_Dyna State
Solid
Ranitidin_Dyna LogP
1.93
Ranitidin_Dyna Dosage Forms
Capsule; Liquid; Solution; Tablet; Syrup
Ranitidin_Dyna Indication
Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).
Ranitidin_Dyna Pharmacology
Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.
Ranitidin_Dyna Absorption
Approximately 50% bioavailability orally.
Ranitidin_Dyna Toxicity
LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.
Ranitidin_Dyna Patient Information
PATIENT INFORMATION
Phenylketonurics: ZANTAC 25 EFFERdose Tablets contain phenylalanine 2.81 mg per 25 mg of ranitidine. ZANTAC 150 EFFERdose Tablets
contain phenylalanine 16.84 mg per 150 mg of ranitidine. ZANTAC EFFERdose Tablets should not be chewed, swallowed whole, or dissolved
on the tongue.
Ranitidin_Dyna Organisms Affected
Humans and other mammals
